BR112017016396A2 - composto, composição farmacêutica, uso de um composto, e, método. - Google Patents

composto, composição farmacêutica, uso de um composto, e, método.

Info

Publication number
BR112017016396A2
BR112017016396A2 BR112017016396A BR112017016396A BR112017016396A2 BR 112017016396 A2 BR112017016396 A2 BR 112017016396A2 BR 112017016396 A BR112017016396 A BR 112017016396A BR 112017016396 A BR112017016396 A BR 112017016396A BR 112017016396 A2 BR112017016396 A2 BR 112017016396A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
disorder
useful
formula
Prior art date
Application number
BR112017016396A
Other languages
English (en)
Inventor
Mackinnon Colin
Carr James
Hargrave Jonathan
Bainbridge Marie
East Stephen
Wellmar Ulf
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of BR112017016396A2 publication Critical patent/BR112017016396A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

trata-se de um composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo. o composto é útil para uso no tratamento contra o câncer, um distúrbio inflamatório, um distúrbio autoimune ou um distúrbio neurodegenerativo.
BR112017016396A 2015-02-03 2015-12-04 composto, composição farmacêutica, uso de um composto, e, método. BR112017016396A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15153627 2015-02-03
PCT/EP2015/078683 WO2016042172A1 (en) 2015-02-03 2015-12-04 Imidazo[2,1-b]thiazole and 5,6-dihydroimidazo[2,1-b]thiazole derivatives useful as s100-inhibitors

Publications (1)

Publication Number Publication Date
BR112017016396A2 true BR112017016396A2 (pt) 2018-03-27

Family

ID=52446251

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017016396A BR112017016396A2 (pt) 2015-02-03 2015-12-04 composto, composição farmacêutica, uso de um composto, e, método.

Country Status (11)

Country Link
US (1) US10385069B2 (pt)
EP (1) EP3253768A1 (pt)
JP (1) JP2018503692A (pt)
KR (1) KR20170113627A (pt)
CN (1) CN107466296A (pt)
AU (1) AU2015316719A1 (pt)
BR (1) BR112017016396A2 (pt)
CA (1) CA2973739A1 (pt)
EA (1) EA201791743A1 (pt)
MX (1) MX2017009597A (pt)
WO (1) WO2016042172A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101948805B1 (ko) 2016-07-05 2019-02-15 한국과학기술연구원 항종양 효과를 갖는 이미다조옥사졸 유도체 및 이를 포함하는 약학적 조성물
US11332479B2 (en) 2016-07-05 2022-05-17 Korea Institute Of Science And Technology Imidazooxazole derivative having antitumor effect, and pharmaceutical composition including same
IL279972A (en) * 2021-01-05 2022-08-01 Anima Biotech Inc Substances that function as modulators of cmyc-mrna translation and their uses in cancer treatment
CN115448863B (zh) * 2022-10-09 2024-03-26 浙江迪邦化工有限公司 一种3,4-二氯苯基硫脲的连续化制备工艺

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4137320A (en) 1974-02-07 1979-01-30 Plantex, Ltd. Pharmaceutical compositions containing imidazo(2,1-b)thiazoles and process for reducing blood sugar levels therewith
EP1387680A4 (en) * 2001-03-05 2010-01-13 Transtech Pharma Inc AGENTS TH RAPEUTICES D RIV S BENZIMIDAZOLE BASE
GB0416396D0 (en) 2004-07-22 2004-08-25 Angeletti P Ist Richerche Bio Therapeutic agents
US7605269B2 (en) 2005-03-23 2009-10-20 Actelion Pharmaceuticals Ltd. Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists

Also Published As

Publication number Publication date
AU2015316719A1 (en) 2017-09-07
US10385069B2 (en) 2019-08-20
JP2018503692A (ja) 2018-02-08
MX2017009597A (es) 2017-11-22
CA2973739A1 (en) 2016-03-24
EA201791743A1 (ru) 2017-12-29
KR20170113627A (ko) 2017-10-12
WO2016042172A1 (en) 2016-03-24
CN107466296A (zh) 2017-12-12
US20180282348A1 (en) 2018-10-04
EP3253768A1 (en) 2017-12-13

Similar Documents

Publication Publication Date Title
CL2018000510A1 (es) Compuestos analogos de nucleosidos sustituidos, inhibidores de prmt5; compuestos intermediarios; composicion farmaceutica; uso para tratar o prevenir una enfermedad autoinmunitaria, inflamatoria, neurodegenerativa o cancer.
BR112017010198A2 (pt) terapia de combinação compreendendo agonistas de ligação a ox40 e antagonistas de ligação ao eixo de pd-1
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
CL2016000925A1 (es) Inhibidores de bromodominio
CL2016001537A1 (es) Inhibidores de syk
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
BR112016013963A2 (pt) terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2016001737A1 (es) Derivados heterocíclicos bicíclicos como inhibidores de bromodominio
BR112016017256A2 (pt) combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer
DOP2017000178A (es) Inhibidores selectivos de bace1
EA201691421A1 (ru) Гетероарилы и их применение
EA201591509A1 (ru) Ингибиторы cdc7
BR112017006940A2 (pt) triazolopirazinonas como inibidores de pde1
BR112017018872A2 (pt) combinação de um antagonista pd-1 e eribulina para tratamento de câncer
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112017007414A2 (pt) combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
EA201692470A1 (ru) Фармацевтические комбинации
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements